Vaccines against zika virus
US11648303B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 24, 2017 |
| Grant date | May 16, 2023 |
| Priority date | — |
| Expiry date | Feb 1, 2038 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An aspect of the present invention is related to nucleic acid constructs capable of expressing a Zika antigen that elicits an immune response in a mammal against Zika virus, and methods of use thereof. Additionally, there are DNA plasmid vaccines capable of generating in a mammal an immune response against a Zika virus, comprising a DNA plasmid and a pharmaceutically acceptable excipient, and methods of use thereof. The DNA plasmid is capable of expressing a Zika antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal that is cross reactive against all Zika strains.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.